Literature DB >> 3196123

The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation.

J A Talcott1, R Finberg, R J Mayer, L Goldman.   

Abstract

To determine whether cancer patients with fever and neutropenia differ in their medical stability, 261 medical records of 184 cancer patients who were hospitalized with fever and neutropenia and treated with conventional antibiotic therapy were studied to determine whether their presenting clinical characteristics influenced the likelihood of subsequent clinical events thought to require urgent medical attention. Overall, serious medical complications, including those without an obvious relationship to infection, occurred in 56 patient courses (21%). We distinguished three clinically determined subgroups of our study population at significantly higher risk than the remaining patient group, which seemed to be at low risk. Major complications occurred in 34 (34%) of 101 inpatients, 12 (55%) of 22 outpatients with concurrent comorbidity requiring inpatient care, and eight (31%) of 26 outpatients without concurrent comorbidity requiring inpatient care but with uncontrolled cancer. However, the remaining patients, who presented as outpatients without significant comorbidity or uncontrolled cancer, had major complications in only 2% of 112 hospitalizations. These results suggest that it may be possible to assess the medical stability of patients with fever and neutropenia based on presenting clinical features. If confirmed prospectively, these results may enable clinicians to identify groups of medically stable patients for whom conventional supportive care, including appropriately administered antibiotics, may be given safely under medical supervision of less intensity or of shorter duration than conventional treatment in the acute-care hospital setting.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3196123

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  52 in total

Review 1.  Management of febrile neutropenia in low risk cancer patients.

Authors:  B A Oppenheim; H Anderson
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

Review 2.  Colony-stimulating factors for the management of neutropenia in cancer patients.

Authors:  David C Dale
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  Safety of early discharge for low-risk patients with febrile neutropenia: a multicenter randomized controlled trial.

Authors:  James A Talcott; Beow Y Yeap; Jack A Clark; Robert D Siegel; Elizabeth Trice Loggers; Charles Lu; Paul A Godley
Journal:  J Clin Oncol       Date:  2011-09-19       Impact factor: 44.544

4.  Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial.

Authors:  Ann M Hendricks; Elizabeth Trice Loggers; James A Talcott
Journal:  J Clin Oncol       Date:  2011-09-19       Impact factor: 44.544

Review 5.  Febrile neutropenia in hematologic malignancies.

Authors:  Michael K Keng; Mikkael A Sekeres
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

6.  The outpatient management of low-risk febrile patients with neutropenia: risk assessment over the telephone.

Authors:  Toshiro Mizuno; Noriyuki Katsumata; Hirofumi Mukai; Chikako Shimizu; Masashi Ando; Toru Watanabe
Journal:  Support Care Cancer       Date:  2006-08-29       Impact factor: 3.603

7.  The prognostic performance of adding patient-reported outcomes to the MASCC risk index to identify low-risk febrile neutropenia patients with solid tumors and lymphomas.

Authors:  Xiao Jun Wang; Denise Yun Ting Goh; Sreemanee Raaj Dorajoo; Alexandre Chan
Journal:  Support Care Cancer       Date:  2017-04-11       Impact factor: 3.603

Review 8.  Outpatient management of febrile neutropenia in children with cancer.

Authors:  Mark Holdsworth; Jeff Hanrahan; Bernadette Albanese; Jami Frost
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

9.  Evaluation of predictors of adverse outcome in febrile neutropenic episodes in pediatric oncology patients.

Authors:  Meenakshi Bothra; Rachna Seth; Arti Kapil; S N Dwivedi; Shinjini Bhatnagar; Immaculata Xess
Journal:  Indian J Pediatr       Date:  2012-12-21       Impact factor: 1.967

10.  Febrile neutropenia studies in Brazil - treatment and cost management based on analyses of cases.

Authors:  Marcelo Bellesso
Journal:  Rev Bras Hematol Hemoter       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.